Engineering Cancer Cells with IL-10 Overexpression for Stronger T Cell Activation

The IL-10 genes introduced and expressed in tumor cells represent a novel promising approach to enhance the antitumor immune response based mainly on T lymphocytes. A study showed Local release of IL-10 from transfected tumor cells induces strong antitumor immune responses and leads to tumor rejection in a variety of mouse mammary adenocarcinoma models. From this, Creative Biolabs has developed a cancer cells engineering platform to gene-modify tumor cells for cancer immunotherapy research.

IL-10 Functions in T cell Activation

Interleukin-10 (IL-10) is a pleiotropic cytokine with important immunoregulatory functions. IL-10 affects many of the cell types in the immune system, including lymphocytes, macrophages, and various other cells. IL-10 is primarily immunosuppressive to APCs, therefore limiting the magnitude of T cell responses and preventing excessive T cell responses. IL-10 also exerts some immune-stimulating effects, such as promoting the generation of cytotoxic T lymphocytes, activating B cells, and up-regulating a small number of genes in TLR-activated phagocytic cells and DCs. In the context of tumors, IL-10 is commonly regarded as an anti-inflammatory, immunosuppressive cytokine that favors tumor escape from immune surveillance, but IL-10 also possesses some immunostimulating properties.

• IL-10 directly inhibits the activation and cytokine secretion of CD4+T cells.
• The role of IL-10 is controversial in CD8+ T cell-mediated anti-tumor immunity. IL-10 plays a stimulatory or suppressive role toward CD8+T cells depending on the situation.
• IL-10 suppresses the expression of inflammatory cytokines such as TNF-α, IL-6, and IL-1 by activated macrophages.

Fig.1 Immune promoting and suppressing mechanisms of IL-10 in cancer immunotherapy. (Ouyang & O’Garra, 2019)

Engineering Cancer Cells with IL-10 Overexpression Service

The IL-10 genes introduced and expressed in tumor cells represent a novel promising approach to enhance the antitumor immune response based mainly on T lymphocytes. With our well-established platform, Creative Biolabs provides end-to-end solutions for the construction of IL10-gene-modified cancer cells. Our scientists have extensive cell culture experience and expertise and introduce the IL-10 gene into the cell of interest by methods such as viral transduction or transfection. Additionally, a series of standard QC assays are performed for releasing the final cell line products.

Our cancer cell engineering services cover a range of different cell lines. The following lists the available cancer cell types:

Creative Biolabs offers a full range of services and consulting expertise so you can get the right technologies and the right advice at exactly the right time to maximize your success. Please let us know the details of your project and we will be happy to provide you with an immediate price quote. If you have any questions about our services, please don’t hesitate to contact us.

Reference

1. Ouyang, W.; O’Garra, A. IL-10 family cytokines IL-10 and IL-22: from basic science to clinical translation. Immunity. 2019, 50(4): 871-91.

For Research Use Only | Not For Clinical Use